SCHEMBL4316646

SCHEMBL4316646

O=C(Nc1cccc2c1C(=O)N(C1CCN(C(=O)O)CC1)C2=O)c1ccc(Cl)s1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 2/20 0.41
HPGD P15428 1/20 0.41
SMN1; SMN2 Q16637 1/20 0.41
ACHE P22303 1/20 0.40
STK33 Q9BYT3 1/20 0.39
F10 P00742 6/20 0.39
MEN1 O00255 1/20 0.39
KMT2A Q03164 1/20 0.39
DDB1 Q16531 1/20 0.39
CRBN Q96SW2 1/20 0.39
MAP1LC3B Q9GZQ8 1/20 0.39
L3MBTL1 Q9Y468 1/20 0.38
PRSS12 P56730 2/20 0.37
F2 P00734 1/20 0.36
HTR2A P28223 1/20 0.36
TMEM97 Q5BJF2 1/20 0.36
SIGMAR1 Q99720 1/20 0.36
KDM4E B2RXH2 1/20 0.36
NPSR1 Q6W5P4 1/20 0.36
BCAT2 O15382 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4303217 0.86 STK33 (0.43) ALDH1A1HPGDSMN1; SMN2ACHESTK33
SCHEMBL6216650 0.85 ALDH1A1 (0.38) ALDH1A1HPGDSMN1; SMN2ACHESTK33
SCHEMBL4305880 0.84 ACHE (0.41) ALDH1A1HPGDSMN1; SMN2ACHESTK33
SCHEMBL4312090 0.84 KMT2A (0.45) ALDH1A1HPGDSMN1; SMN2ACHESTK33
SCHEMBL4307094 0.84 F10 (0.45) ALDH1A1HPGDSMN1; SMN2ACHESTK33
SCHEMBL6640950 0.78 CRBN (0.39) ALDH1A1HPGDSMN1; SMN2ACHESTK33
SCHEMBL4312080 0.77 ACHE (0.56) ALDH1A1HPGDSMN1; SMN2ACHESTK33
SCHEMBL4302308 0.77 ACHE (0.56) ALDH1A1HPGDSMN1; SMN2ACHEF10
SCHEMBL4304697 0.75 ACHE (0.45) ALDH1A1HPGDSMN1; SMN2ACHESTK33
SCHEMBL4303895 0.75 F10 (0.56) ALDH1A1HPGDSMN1; SMN2ACHESTK33

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7482472-B2 Substituted isoindoles and their use BAYER HEALTHCARE AG (DE) 2009-01-27 US disclosed
US-20080039446-A1 Substituted isoindoles and their use BAYER HEALTHCARE AG (DE) 2008-02-14 US disclosed
US-7189738-B2 Substituted isoindoles and their use thereof BAYER HEALTHCARE AG (DE) 2007-03-13 US disclosed
US-20040215019-A1 Substituted isoindoles and the e use thereof BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) 2004-10-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080039446-A1 Substituted isoindoles and their use F2, F12, TFPI2 ALDH1A1 346/4885HPGD 195/4885SMN1; SMN2 1980/4885
US-20040215019-A1 Substituted isoindoles and the e use thereof F2, F12, F5 ALDH1A1 166/4885HPGD 433/4885SMN1; SMN2 2271/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.